Galapagos (GLPG) Projected to Post Quarterly Earnings on Wednesday

Galapagos (NASDAQ:GLPG - Get Free Report) is projected to post its quarterly earnings results after the market closes on Wednesday, April 23rd. Analysts expect Galapagos to post earnings of ($0.19) per share and revenue of $72.22 million for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Galapagos Trading Up 0.7 %

Shares of GLPG traded up $0.16 during mid-day trading on Friday, reaching $24.66. The company's stock had a trading volume of 252,010 shares, compared to its average volume of 201,496. Galapagos has a 52 week low of $22.36 and a 52 week high of $31.23. The company's fifty day moving average price is $25.37 and its two-hundred day moving average price is $26.30.

Wall Street Analysts Forecast Growth

GLPG has been the topic of a number of recent research reports. Barclays reaffirmed an "underweight" rating on shares of Galapagos in a research note on Thursday, January 23rd. TD Cowen lowered Galapagos from a "strong-buy" rating to a "strong sell" rating in a research note on Thursday, January 9th. Finally, Morgan Stanley lowered shares of Galapagos from an "equal weight" rating to an "underweight" rating and lowered their price target for the company from $31.00 to $22.00 in a report on Friday, February 14th. Four analysts have rated the stock with a sell rating and four have given a hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $25.33.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.